Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

NCT05303090 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05303090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Lead sponsor
Fudan University
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2022
Completion date
April 23, 2024
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma